Loading…
Loading…
EW does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for EW and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for EW and 80,000+ other tickers.
See exactly how EW's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for EW and 80,000+ other tickers.
Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions. Their structural heart disease portfolio encompasses transcatheter heart valve replacement systems designed for minimally invasive procedures, as well as transcatheter repair and replacement options specifically targeting mitral…
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences Corporation (NYSE: EW) will participate in the Deutsche Bank Healthcare Summit on Wednesday, Sept. 16, 2026.Bernard Zovighian, chief executive officer, is scheduled to present at 10:00 a.m. ET. Doretta Mistras, chief financial officer, will also participate in the conference. A live webcast of the presentation will be available on the Edwards Lifesciences investor relations website at http://ir.edwards.com/, with an archived version accessibl.
Beacon Pointe Advisors LLC bought a new position in Edwards Lifesciences Corporation (NYSE: EW) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 128,603 shares of the medical research company's stock, valued at approximately $11,632,000. A number of
On August 26, 2026, we delve into the DCF analysis for Edwards Lifesciences Corp (EW), a company that has seen a price performance of +12.4% over the past year
Bank of Nova Scotia bought a new position in Edwards Lifesciences Corporation (NYSE: EW) during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 60,417 shares of the medical research company's stock, valued at approximately $5,465,000. Several other hedge funds also recently made